Market Place
Sourcing Support
Walden Biosciences Enrolls First Cohort In Ph 2 Kidney Study
30 Sep 2024 //
GLOBENEWSWIRE
Walden Biosciences teams up with Primula for kidney disease study
14 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Walden Bio Announces Collaboration On suPAR Role In Kidney Disease
13 May 2024 //
GLOBENEWSWIRE
Walden Positive WAL0921 Kidney Disease Phase 1+ Data
15 Apr 2024 //
GLOBENEWSWIRE
Walden Bio Expands Research Collaboration with the University of Michigan
10 Jan 2024 //
GLOBENEWSWIRE
Walden Biosciences to Host Virtual Event on November 14, 2023
07 Nov 2023 //
GLOBENEWSWIRE
Walden Biosciences Announces First Subject Dosed in Phase 1 Trial of WAL0921
05 Jun 2023 //
GLOBENEWSWIRE
Walden Biosciences Promotes Curt Dewan, CFA to Chief Financial Officer
05 Apr 2023 //
GLOBENEWSWIRE
Walden To Present at Annual Chronic Kidney Disease Drug Development Summit
08 Mar 2023 //
GLOBENEWSWIRE
Walden Biosciences Announces Presentation at Antibody Engineering & Therapeutics
02 Dec 2022 //
GLOBENEWSWIRE
Walden Biosciences Announces Participation at October Investor Conferences
13 Oct 2022 //
GLOBENEWSWIRE
Walden Biosciences Announces Participation in Citi’s 17th Annual BioPharma
31 Aug 2022 //
GLOBENEWSWIRE
Walden Biosciences Announces Presentation at Canaccord Conference
04 Aug 2022 //
GLOBENEWSWIRE
Walden Biosciences Announces Research Collaboration with University of Michigan
05 Jul 2022 //
GLOBENEWSWIRE
Walden Biosciences Announces Presentation at 32nd Annual Oppenheimer Conference
11 Mar 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.